Alembic Pharma gets USFDA nod for generic chronic iron overload treatment tablets - (Business Line via NewsPoints Desk)

  • Alembic Pharmaceuticals said it received FDA approvals for deferasirox used for the treatment of chronic iron overload due to blood transfusions in patients over two years of age, reported Business Line.

  • The drug is also used to treat chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia syndromes.

  • Deferasirox is a generic version of Novartis' Jadenu tablets and Exjade tablets for oral suspension.

  • Alembic said the estimated market size for deferasirox tablets was $ 415 million for the 12 months ended December 2018, and $135 million for deferasirox tablets for oral suspension.

To read more NewsPoints articles, click here.